Research map: Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer

Back to the article

Papers in this map

  1. Tracking the Evolution of Non–Small-Cell Lung Cancer · Mariam Jamal‐Hanjani · 2017 · 2503 citations · Cited by this paper
  2. Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma · 2026 · Related
  3. Lung adenocarcinoma promotion by air pollutants · William D. Hill · 2023 · 810 citations · Cited by this paper
  4. Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT · 2026 · Related
  5. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study · Gee‐Chen Chang · 2023 · 177 citations · Cited by this paper
  6. BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer · 2026 · Related
  7. High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome · Laura Mezquita · 2020 · 57 citations · Cited by this paper
  8. Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients · 2026 · Related
  9. The psychosocial effects of the Li-Fraumeni Education and Early Detection (LEAD) program on individuals with Li-Fraumeni syndrome · Jessica L. Ross · 2017 · 54 citations · Cited by this paper
  10. Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives · 2026 · Related
  11. Update on Cancer Screening Recommendations for Individuals with Li–Fraumeni Syndrome · Maria Isabel Achatz · 2025 · 46 citations · Cited by this paper
  12. Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study · 2026 · Related
  13. Characteristics of Li‐Fraumeni syndrome in Japan: A review study by the special committee of JSHT · Michinori Funato · 2021 · 23 citations · Cited by this paper
  14. Time-dependent bias in local consolidative therapy for EGFR-mutant metastatic non-small cell lung cancer · 2026 · Related
  15. Genomic Profiles of Pathogenic and Moderate-Penetrance Germline Variants Associated With Risk of Early-Onset Lung Adenocarcinoma · Hourin Cho · 2025 · 12 citations · Cited by this paper
  16. Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy · 2026 · Related
  17. Characterizing Lung Cancer in Li-Fraumeni Syndrome · Jessica N. Hatton · 2024 · 4 citations · Cited by this paper
  18. CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer · 2026 · Related
  19. Untitled · Cited by this paper
  20. First-line treatment for unresectable pulmonary lymphoepithelial carcinoma: A real-world comparison of platinum-based doublet chemotherapy with or without PD-1 inhibitors · 2026 · Related

Source: OpenAlex (CC0)